Search
Arcturus Therapeutics Holdings Inc
ARCTAdd to Watchlist
10.620USD
+0.270+2.61%
Market hours 11/09, 10:51（ET）
301.82MMarket Cap
LossP/E TTM
Arcturus Therapeutics Holdings Inc (ARCT) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Arcturus Therapeutics Holdings Inc in the past month.
Buy
4 Strong Buy
7 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
24.222USD+119.60%
ARCT Analyst Recommendation Trends
In the current month, ARCT has received 7 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ARCT average Analyst price target in the last month is 24.222.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
4
4
3
3
3
3
3
3
7
7
6
6
6
7
7
6
2
2
3
3
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
12
12
12
13
13
12
ARCT Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, ARCT EPS is projected to reach -0.887 in FY2026Q4, following reported EPS of -0.261 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-1.09
-1.00
-0.68
-0.89
-0.90
Actual
-0.95
-0.84
-0.26
--
--
Surprise
+12.85%
+16.20%
+61.59%
--
--
FAQs
What is Arcturus Therapeutics Holdings Inc's expected revenue for the next quarter?
Arcturus Therapeutics Holdings Inc's expected revenue is 4.97M.
What is Arcturus Therapeutics Holdings Inc's price target?
Analysts forecast that Arcturus Therapeutics Holdings Inc's price target is USD 24.22, with the highest forecast at USD 41.00 and the lowest forecast at USD 9.00.
How have Arcturus Therapeutics Holdings IncARCT's recent earnings per share performed?
The market expectation was USD -0.26, while Arcturus Therapeutics Holdings IncARCT's earnings per share (EPS) for the previous quarter was USD -0.84. EPS for the next quarter is expected at USD -0.89.
What is the analyst rating for Arcturus Therapeutics Holdings Inc?
Based on the ratings of Arcturus Therapeutics Holdings Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.